ijms-logo

Journal Browser

Journal Browser

Pulmonary Arterial Hypertension: From Genetics to Epigenetics

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Genetics and Genomics".

Deadline for manuscript submissions: closed (20 January 2023) | Viewed by 13126

Special Issue Editors


E-Mail Website
Guest Editor
Institute of Clinical Physiology, National Council Research, 56124 Pisa, Italy
Interests: epigenetic; noncoding RNAs; RNA sequencing; gene expression; cardiovascular disease; congenital cardiac disease; animal model; zebrafish
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
CNR Institute of Clinical Physiology, Via G.Moruzzi 1, 56100 Pisa, Italy
Interests: post-ischemic cardiac remodeling; pre-clinical animal models; signaling pathways; miRNA/gene regulatory networks
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Pulmonary arterial hypertension (PAH) is a serious cardiopulmonary–vascular condition with no readily available cure. It is characterized by progressive angioproliferative remodeling of the precapillary vessel, resulting in vasoconstriction and a significant increase in pulmonary vascular resistance, which ultimately leads to right ventricle failure and premature death. The obliterative remodeling is sustained by dysfunctions of the lung vessel cells that release mitogens and vasoconstrictors with an imbalance of cell proliferation versus cell death. The etiology of PAH is complex and may be mediated by the interplay of a predisposed genetic background, epigenetic state and injurious events. Most of the genetic mutations associated with PAH have been identified in genes of the TGF beta superfamily that code for receptors involved in the regulation of cell proliferation and endothelial to mesenchimal transition; the most characterized and representative gene in this family is the Bone Morphogenetic Protein Receptor 2 (BMPR2). Other genes identified as involved in proliferative vasoconstrictive signaling pathways are Caveolin 1, Endoglin, Translation Initiation Factor 2 Alpha Kinase 4, Kruppel Like Factor 2, Potassium Two Pore Domain Channel Subfamily K Member 3 and others. On the epigenetic side, alterations in the DNA methylation state at key gene loci, as well as modifications of the histone H1 and histone deacetylase levels, have been shown to play important roles in the hyperproliferative and veno-occlusive processes. Moreover, dysregulation of microRNA networks or mutations in microRNA-targeted sequences represent other important epigenetic players in the pathogenesis of PAH. Epigenetic mechanisms might explain the great variability in susceptibility to environmental cues in PAH progression and severity and might be relevant to the female predisposition to PAH and the incomplete penetrance of BMPR2 mutations in familial PAH. Overall, these observations clearly indicate that a global perspective of the molecular network underlying the PAH phenotype is necessary to design novel therapeutic strategies.

This Special Issue of IJMS, “Pulmonary arterial hypertension: from genetics to epigenetics”, will cover a selection of recent research topics related to advances in the comprehension of the genetic and epigenetic mechanisms involved in the establishment of PAH. Up-to-date review articles, commentaries and experimental papers are all welcome.

Dr. Letizia Pitto
Dr. Giuseppina Nicolini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (4 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 1830 KiB  
Article
Clinical Implications of the Genetic Background in Pediatric Pulmonary Arterial Hypertension: Data from the Spanish REHIPED Registry
by Alejandro Cruz-Utrilla, Natalia Gallego-Zazo, Jair Antonio Tenorio-Castaño, Inmaculada Guillén, Alba Torrent-Vernetta, Amparo Moya-Bonora, Carlos Labrandero, María Elvira Garrido-Lestache Rodríguez-Monte, Alejandro Rodríguez-Ogando, María del Mar Rodríguez Vázquez Del Rey, Juana Espín, Beatriz Plata-Izquierdo, María Álvarez-Fuente, Antonio Moreno-Galdó, Pilar Escribano-Subias and María Jesús Del Cerro Marín
Int. J. Mol. Sci. 2022, 23(18), 10433; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms231810433 - 09 Sep 2022
Cited by 4 | Viewed by 2214
Abstract
Background: Pulmonary arterial hypertension (PAH) is a severe and rare disease with an important genetic background. The influence of genetic testing in the clinical classification of pediatric PAH is not well known and genetics could influence management and prognosis. Objectives: The aim of [...] Read more.
Background: Pulmonary arterial hypertension (PAH) is a severe and rare disease with an important genetic background. The influence of genetic testing in the clinical classification of pediatric PAH is not well known and genetics could influence management and prognosis. Objectives: The aim of this work was to identify the molecular fingerprint of PH children in the REgistro de pacientes con HIpertensión Pulmonar PEDiátrica (REHIPED), and to investigate if genetics could have an impact in clinical reclassification and prognosis. Methods: We included pediatric patients with a genetic analysis from REHIPED. From 2011 onward, successive genetic techniques have been carried out. Before genetic diagnosis, patients were classified according to their clinical and hemodynamic data in five groups. After genetic analysis, the patients were reclassified. The impact of genetics in survival free of lung transplantation was estimated by Kaplan–Meier curves. Results: Ninety-eight patients were included for the analysis. Before the genetic diagnoses, there were idiopathic PAH forms in 53.1%, PAH associated with congenital heart disease in 30.6%, pulmonary veno-occlusive disease—PVOD—in 6.1%, familial PAH in 5.1%, and associated forms with multisystemic disorders—MSD—in 5.1% of the patients. Pathogenic or likely pathogenic variants were found in 44 patients (44.9%). After a genetic analysis, 28.6% of the cohort was “reclassified”, with the groups of heritable PAH, heritable PVOD, TBX4, and MSD increasing up to 18.4%, 8.2%, 4.1%, and 12.2%, respectively. The MSD forms had the worst survival rates, followed by PVOD. Conclusions: Genetic testing changed the clinical classification of a significant proportion of patients. This reclassification showed relevant prognostic implications. Full article
(This article belongs to the Special Issue Pulmonary Arterial Hypertension: From Genetics to Epigenetics)
Show Figures

Figure 1

Review

Jump to: Research

13 pages, 674 KiB  
Review
Role of microRNAs in Congenital Diaphragmatic Hernia-Associated Pulmonary Hypertension
by Flaminia Pugnaloni, Irma Capolupo, Neil Patel, Paola Giliberti, Andrea Dotta, Pietro Bagolan and Florian Kipfmueller
Int. J. Mol. Sci. 2023, 24(7), 6656; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms24076656 - 03 Apr 2023
Cited by 2 | Viewed by 1469
Abstract
Epigenetic regulators such as microRNAs (miRNAs) have a key role in modulating several gene expression pathways and have a role both in lung development and function. One of the main pathogenetic determinants in patients with congenital diaphragmatic hernia (CDH) is pulmonary hypertension (PH), [...] Read more.
Epigenetic regulators such as microRNAs (miRNAs) have a key role in modulating several gene expression pathways and have a role both in lung development and function. One of the main pathogenetic determinants in patients with congenital diaphragmatic hernia (CDH) is pulmonary hypertension (PH), which is directly related to smaller lung size and pulmonary microarchitecture alterations. The aim of this review is to highlight the importance of miRNAs in CDH-related PH and to summarize the results covering this topic in animal and human CDH studies. The focus on epigenetic modulators of CDH-PH offers the opportunity to develop innovative diagnostic tools and novel treatment modalities, and provides a great potential to increase researchers’ understanding of the pathophysiology of CDH. Full article
(This article belongs to the Special Issue Pulmonary Arterial Hypertension: From Genetics to Epigenetics)
Show Figures

Figure 1

24 pages, 2441 KiB  
Review
Molecular Pathways in Pulmonary Arterial Hypertension
by Aangi J. Shah, Mounica Vorla and Dinesh K. Kalra
Int. J. Mol. Sci. 2022, 23(17), 10001; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms231710001 - 02 Sep 2022
Cited by 15 | Viewed by 4571
Abstract
Pulmonary arterial hypertension is a multifactorial, chronic disease process that leads to pulmonary arterial endothelial dysfunction and smooth muscular hypertrophy, resulting in impaired pliability and hemodynamics of the pulmonary vascular system, and consequent right ventricular dysfunction. Existing treatments target limited pathways with only [...] Read more.
Pulmonary arterial hypertension is a multifactorial, chronic disease process that leads to pulmonary arterial endothelial dysfunction and smooth muscular hypertrophy, resulting in impaired pliability and hemodynamics of the pulmonary vascular system, and consequent right ventricular dysfunction. Existing treatments target limited pathways with only modest improvement in disease morbidity, and little or no improvement in mortality. Ongoing research has focused on the molecular basis of pulmonary arterial hypertension and is going to be important in the discovery of new treatments and genetic pathways involved. This review focuses on the molecular pathogenesis of pulmonary arterial hypertension. Full article
(This article belongs to the Special Issue Pulmonary Arterial Hypertension: From Genetics to Epigenetics)
Show Figures

Figure 1

15 pages, 375 KiB  
Review
Epigenetic Regulation of Endothelial Dysfunction and Inflammation in Pulmonary Arterial Hypertension
by Jaylen Hudson and Laszlo Farkas
Int. J. Mol. Sci. 2021, 22(22), 12098; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms222212098 - 09 Nov 2021
Cited by 12 | Viewed by 3727
Abstract
Once perceived as a disorder treated by vasodilation, pulmonary artery hypertension (PAH) has emerged as a pulmonary vascular disease with severe endothelial cell dysfunction. In the absence of a cure, many studies seek to understand the detailed mechanisms of EC regulation to potentially [...] Read more.
Once perceived as a disorder treated by vasodilation, pulmonary artery hypertension (PAH) has emerged as a pulmonary vascular disease with severe endothelial cell dysfunction. In the absence of a cure, many studies seek to understand the detailed mechanisms of EC regulation to potentially create more therapeutic options for PAH. Endothelial dysfunction is characterized by complex phenotypic changes including unchecked proliferation, apoptosis-resistance, enhanced inflammatory signaling and metabolic reprogramming. Recent studies have highlighted the role of epigenetic modifications leading to pro-inflammatory response pathways, endothelial dysfunction, and the progression of PAH. This review summarizes the existing literature on epigenetic mechanisms such as DNA methylation, histone modifications, and non-coding RNAs, which can lead to aberrant endothelial function. Our goal is to develop a conceptual framework for immune dysregulation and epigenetic changes in endothelial cells in the context of PAH. These studies as well as others may lead to advances in therapeutics to treat this devastating disease. Full article
(This article belongs to the Special Issue Pulmonary Arterial Hypertension: From Genetics to Epigenetics)
Back to TopTop